Expression of erythropoietin receptor splice variants in human cancer

被引:92
作者
Arcasoy, MO
Jiang, XH
Haroon, ZA
机构
[1] Duke Univ, Sch Med, Dept Med, Div Hematol Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Dept Med, Dept Transplantat, Durham, NC 27710 USA
[3] Synergen Inc, San Francisco, CA 94025 USA
关键词
erythropoietin; erythropoietin receptor; cancer cells; alternative splicing;
D O I
10.1016/S0006-291X(03)01303-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Erythropoietin (EPO) regulates mammalian erythropoiesis by binding to its transmembrane receptor EPOR. Recent studies demonstrated functional EPOR expression in human cancer cells. Recombinant human EPO was reported to stimulate the proliferation of monolayer cultures of breast and renal carcinoma cells. Furthermore, administration of EPO-EPOR antagonists delayed the growth of uterine, ovarian, and mammary carcinoma cells in experimental animal models. In this study, we show EPOR transcript and protein expression in breast, colon, lung, ovary, and prostate cancer cells. Using reverse transcription-polymerase chain reaction. we isolated and characterized several novel cDNAs for EPOR splice variants expressed in cancer cells. Deduced amino acid sequences of the cDNAs revealed splice variants encoding soluble EPOR or membrane-bound EPOR peptides with intra-cytoplasmic, carboxy-terminal truncations. These findings indicate the expression of multiple EPOR isoforms in human cancer cells that may modulate the cellular effects of recombinant human EPO or EPO-EPOR antagonists. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:999 / 1007
页数:9
相关论文
共 52 条
  • [1] Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma
    Acs, G
    Zhang, PJ
    Rebbeck, TR
    Acs, P
    Verma, A
    [J]. CANCER, 2002, 95 (05) : 969 - 981
  • [2] Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression
    Acs, G
    Zhang, PJ
    McGrath, CM
    Acs, P
    McBroom, J
    Mohyeldin, A
    Liu, SZ
    Lu, HS
    Verma, A
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) : 1789 - 1806
  • [3] Acs G, 2001, CANCER RES, V61, P3561
  • [4] ERYTHROPOIETIN HAS A MITOGENIC AND POSITIVE CHEMOTACTIC EFFECT ON ENDOTHELIAL-CELLS
    ANAGNOSTOU, A
    LEE, ES
    KESSIMIAN, N
    LEVINSON, R
    STEINER, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (15) : 5978 - 5982
  • [5] Functional significance of erythropoietin receptor expression in breast cancer
    Arcasoy, MO
    Amin, K
    Karayal, AF
    Chou, SC
    Raleigh, JA
    Varia, MA
    Haroon, ZA
    [J]. LABORATORY INVESTIGATION, 2002, 82 (07) : 911 - 918
  • [6] A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis
    Arcasoy, MO
    Karayal, AF
    Segal, HM
    Sinning, JG
    Forget, BG
    [J]. BLOOD, 2002, 99 (08) : 3066 - 3069
  • [7] Arcasoy MO, 2001, BLOOD, V98, p822A
  • [8] Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression
    Arcasoy, MO
    Maun, NA
    Perez, L
    Forget, BG
    Berliner, N
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 67 (02) : 77 - 87
  • [9] Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene
    Arcasoy, MO
    Degar, BA
    Harris, KW
    Forget, BG
    [J]. BLOOD, 1997, 89 (12) : 4628 - 4635